271 related articles for article (PubMed ID: 18398609)
1. Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2'-deoxycytidine.
Lemaire M; Momparler LF; Raynal NJ; Bernstein ML; Momparler RL
Cancer Chemother Pharmacol; 2009 Feb; 63(3):411-6. PubMed ID: 18398609
[TBL] [Abstract][Full Text] [Related]
2. Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase.
Laliberté J; Marquez VE; Momparler RL
Cancer Chemother Pharmacol; 1992; 30(1):7-11. PubMed ID: 1375134
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by zebularine on L1210 leukemia.
Lemaire M; Momparler LF; Bernstein ML; Marquez VE; Momparler RL
Anticancer Drugs; 2005 Mar; 16(3):301-8. PubMed ID: 15711182
[TBL] [Abstract][Full Text] [Related]
4. Drug resistance to 5-aza-2'-deoxycytidine, 2',2'-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells.
Eliopoulos N; Cournoyer D; Momparler RL
Cancer Chemother Pharmacol; 1998; 42(5):373-8. PubMed ID: 9771951
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia.
Momparler RL; Côté S; Eliopoulos N
Leukemia; 1997 Mar; 11 Suppl 1():S1-6. PubMed ID: 9130684
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the antileukemic activity of 5-AZA-2'-deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia.
Momparler RL; Momparler LF; Samson J
Leuk Res; 1984; 8(6):1043-9. PubMed ID: 6083417
[TBL] [Abstract][Full Text] [Related]
7. Induction of cytidine deaminase in HL-60 myeloid leukemic cells by 5-aza-2'-deoxycytidine.
Momparler RL; Laliberté J
Leuk Res; 1990; 14(9):751-4. PubMed ID: 1700230
[TBL] [Abstract][Full Text] [Related]
8. Selection of drug-resistant transduced cells with cytosine nucleoside analogs using the human cytidine deaminase gene.
Beauséjour CM; Eliopoulos N; Momparler L; Le NL; Momparler RL
Cancer Gene Ther; 2001 Sep; 8(9):669-76. PubMed ID: 11593336
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of the antileukemic activity of 5-aza-2'-deoxycytidine by cyclopentenyl cytosine in HL-60 leukemic cells.
Bouffard DY; Momparler LF; Momparler RL
Anticancer Drugs; 1994 Apr; 5(2):223-8. PubMed ID: 7519483
[TBL] [Abstract][Full Text] [Related]
10. Interaction of 5-aza-2'-deoxycytidine with amsacrine or 1,25-dihydroxyvitamin D3 on HL-60 myeloid leukemic cells and inhibitors of cytidine deaminase.
Momparler RL; Doré BT; Labiberté J; Momparler LF
Leukemia; 1993 May; 7 Suppl 1():17-20. PubMed ID: 7683351
[TBL] [Abstract][Full Text] [Related]
11. 3-Deazauridine enhances the antileukemic action of 5-aza-2'-deoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase.
Raynal NJ; Momparler LF; Rivard GE; Momparler RL
Leuk Res; 2011 Jan; 35(1):110-8. PubMed ID: 20510451
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by phenylbutyrate on L1210 leukemic cells.
Lemaire M; Momparler LF; Farinha NJ; Bernstein M; Momparler RL
Leuk Lymphoma; 2004 Jan; 45(1):147-54. PubMed ID: 15061212
[TBL] [Abstract][Full Text] [Related]
13. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines.
Stresemann C; Brueckner B; Musch T; Stopper H; Lyko F
Cancer Res; 2006 Mar; 66(5):2794-800. PubMed ID: 16510601
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia.
Momparler RL; Côté S; Eliopoulos N
Leukemia; 1997 Feb; 11(2):175-80. PubMed ID: 9009076
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2'-deoxycytidine as a possible mechanism of chemotherapeutic action.
Wilson VL; Jones PA; Momparler RL
Cancer Res; 1983 Aug; 43(8):3493-6. PubMed ID: 6190553
[TBL] [Abstract][Full Text] [Related]
16. Cellular differentiation, cytidine analogs and DNA methylation.
Jones PA; Taylor SM
Cell; 1980 May; 20(1):85-93. PubMed ID: 6156004
[TBL] [Abstract][Full Text] [Related]
17. Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine.
Chuang JC; Yoo CB; Kwan JM; Li TW; Liang G; Yang AS; Jones PA
Mol Cancer Ther; 2005 Oct; 4(10):1515-20. PubMed ID: 16227400
[TBL] [Abstract][Full Text] [Related]
18. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells.
Billam M; Sobolewski MD; Davidson NE
Breast Cancer Res Treat; 2010 Apr; 120(3):581-92. PubMed ID: 19459041
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology of 5-Aza-2'-deoxycytidine (decitabine).
Momparler RL
Semin Hematol; 2005 Jul; 42(3 Suppl 2):S9-16. PubMed ID: 16015507
[TBL] [Abstract][Full Text] [Related]
20. Creation of zebularine-resistant human cytidine deaminase mutants to enhance the chemoprotection of hematopoietic stem cells.
Ruan H; Qiu S; Beard BC; Black ME
Protein Eng Des Sel; 2016 Dec; 29(12):573-582. PubMed ID: 27160178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]